drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (engineered NK cells)
drug_description
Allogeneic, cord blood–derived NK cell therapy engineered to express an HLA-A*02:01–restricted NY-ESO-1–specific T-cell receptor plus IL-15 to enhance activation, proliferation, and persistence; mediates tumor killing via the introduced TCR and native NK cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
ENGINEERED TCR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic cord blood–derived NK cells engineered to express an HLA-A*02:01–restricted NY-ESO-1–specific TCR plus IL-15. The introduced TCR enables recognition of NY-ESO-1 peptide–HLA complexes on tumor cells, while IL-15 enhances activation, proliferation, and persistence. Tumor killing occurs via TCR-driven cytotoxicity and native NK effector functions (perforin/granzyme, activating receptors such as NKG2D).
drug_name
NY-ESO-1 TCR/IL-15 NK cells
nct_id_drug_ref
NCT06066359